Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business

Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business

Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs. Transaction includes sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. Transaction...

menu
menu